Lupin inches up on getting USFDA’s approval for Cinacalcet Tablets

04 Jul 2019 Evaluate

Lupin is currently trading at Rs. 753.05, up by 0.25 points or 0.03% from its previous closing of Rs. 752.80 on the BSE.

The scrip opened at Rs. 759.95 and has touched a high and low of Rs. 759.95 and Rs. 748.75 respectively. So far 42077 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.

Last one week high and low of the scrip stood at Rs. 789.90 and Rs. 747.20 respectively. The current market cap of the company is Rs. 34181.92 crore.

The promoters holding in the company stood at 46.97%, while Institutions and Non-Institutions held 38.07% and 14.96% respectively.

Lupin has received approval for its Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg from the United States Food and Drug Administration (USFDA). Lupin’s Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, is the generic version of Sensipar Tablets, 30 mg, 60 mg, and 90 mg, of Amgen Inc.

It is indicated in the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, hypercalcemia in adult patients with Parathyroid Carcinoma. Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, had annual sales of approximately $1,527 million in the US (IQVIA MAT March 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2166.10 -12.10 (-0.56%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×